Who owns BridgeBio Pharma, Inc. (BBI)? Elite investor 13F holders
6 tracked elite investors reported holding BridgeBio Pharma, Inc as of 2026-09-30, including Viking Global Investors, D.E. Shaw, Renaissance Technologies LLC, Bridgewater Associates, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
6 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Viking Global Investors | BRIDGEBIO PHARMA INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 644328010.00 USD | 9792219.000000 | Shares | reduce | Original filing |
| D.E. Shaw | BRIDGEBIO PHARMA INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 146285902.00 USD | 2223190.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | BRIDGEBIO PHARMA INC | SHARE | 2026-09-30 | 2026-11-12 00:00:00 | 56360727.00 USD | 856546.000000 | Shares | reduce | Original filing |
| Bridgewater Associates | BRIDGEBIO PHARMA INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 45772980.00 USD | 695638.000000 | Shares | add | Original filing |
| D.E. Shaw | BRIDGEBIO PHARMA INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 7527268.00 USD | 5000000.000000 | Principal | buy | Original filing |
| Gotham Asset Management | BRIDGEBIO PHARMA INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 457244.00 USD | 6949.000000 | Shares | buy | Original filing |
| Polen Capital Management | BRIDGEBIO PHARMA INC | SHARE | 2026-09-30 | 2026-11-13 00:00:00 | 296758.00 USD | 4510.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.